To recover your password please fill in your email address
Please fill in below form to create an account with us
Adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial (ANZUP1301).
See ANZCTR for full trial details >
To determine the efficacy and safety of MMC in addition to BCG in patients with non-muscle, invasive bladder cancer.
Cancer Australia and National Health and Medical Research Council (NHMRC)
Adults with resected, high-risk non-muscle, invasive bladder cancer (high grade Ta or any grade T1) suitable for intravesical chemotherapy treatment.
Australian Lead Group:
Prof Dickon Hayne